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Abstract
Background: Despite national recommendations, as of 2009 human papillomavirus (HPV) vaccination rates were
low with < 30% of adolescent girls fully vaccinated. Research on barriers to vaccination has focused separately on
parents, adolescents, or clinicians and not on the decision making process among all participants at the point of
care. By incorporating three distinct perspectives, we sought to generate hypotheses to inform interventions to
increase vaccine receipt.
Methods: Between March and June, 2010, we conducted qualitative interviews with 20 adolescent-mother-clinician
triads (60 individual interviews) directly after a preventive visit with the initial HPV vaccine due. Interviews followed
a guide based on published HPV literature, involved 9 practices, and continued until saturation of the primary
themes was achieved. Purposive sampling balanced adolescent ages and practice type (urban resident teaching
versus non-teaching). Using a modified grounded theory approach, we analyzed data with NVivo8 software both
within and across triads to generate primary themes.
Results: The study population was comprised of 20 mothers (12 Black, 9 < high school diploma), 20 adolescents (ten
11-12 years old), and 20 clinicians (16 female). Nine adolescents received the HPV vaccine at the visit, eight of whom
were African American. Among the 11 not vaccinated, all either concurrently received or were already up-to-date on
Tdap and MCV4. We did not observe systematic patterns of vaccine acceptance or refusal based on adolescent age
or years of clinician experience. We identified 3 themes: (1) Parents delayed, rather than refused vaccination, and
when they expressed reluctance, clinicians were hesitant to engage them in discussion. (2) Clinicians used one of
two strategies to present the HPV vaccine, either presenting it as a routine vaccine with no additional information or
presenting it as optional and highlighting risks and benefits. (3) Teens considered themselves passive participants in
decision making, even when parents and clinicians reported including them in the process.
Conclusions: Programs to improve HPV vaccine delivery in primary care should focus on promoting effective
parent-clinician communication. Research is needed to evaluate strategies to help clinicians engage reluctant
parents and passive teens in discussion and measure the impact of distinct clinician decision making approaches
on HPV vaccine delivery.
Background
Since 2006, vaccines have been licensed to prevent cervi-
cal cancer, genital cancers, precancerous lesions, genital
warts, and other conditions caused by human papilloma-
virus (HPV) [1-3]. As a preventive intervention, the HPV
vaccine is especially important since HPV is the most
common sexually transmitted infection [4] and is often
acquired shortly following sexual initiation [5]. The
population at risk for acquiring HPV includes nearly half
of all US high school students, [6] and an estimated
33.8% of 14 to 24 year olds are currently infected [4].
Multiple clinical trials have demonstrated the safety and
efficacy of the HPV vaccine,[7,8] and national guidelines
recommend the HPV vaccine for girls 11-12 years of age
as part of the routine adolescent vaccine platform [9].
However, despite these recommendations, rates of HPV
vaccination remain the lowest of all adolescent vaccines
according to the 2009 National Immunization Survey
[10,11]. As of 2009, only 27% of US girls between 13 and
17 years of age are fully vaccinated. Although the HPV
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any medium, provided the original work is properly cited.vaccine is relatively new, this finding is especially concern-
ing since full protection requires three doses given over a
minimum of six months [9].
In an effort to increase vaccination rates, numerous stu-
dies have examined factors associated with the acceptabil-
ity of HPV vaccine among parents and adolescents, and
factors associated with clinician intention to vaccinate,
both of which were high [12,13]. Importantly, parents,
teens, and clinicians all report that their views on accept-
ability are influenced by each other. Effective communica-
tion about HPV among parents, teens and providers has
been linked to vaccine acceptability and receipt [14,15].
Parents and adolescents are positively influenced by get-
ting a doctor’s recommendation,[16-18] adolescents stress
the importance of parents, partners and other significant
people supporting vaccination, especially mothers,
[15,19-21] and clinicians’ intention to vaccinate depends
in part on their perception of parents’ concerns regarding
safety and efficacy [22-24]. Clinicians are also affected by
normative influences such as national guidelines and
recommendations [24,25].
Prompted by the discrepancy between high reported
vaccine acceptability and intention to vaccinate and low
vaccination rates, we conducted a qualitative study using
individual interviews with mother, adolescent, and primary
care clinician triads to better understand decision making
at the point of care. Discussion about barriers to vaccine
receipt has generally focused separately on parents, clini-
cians or adolescents. We studied triads to move beyond
conceptualizations of barriers among individuals, and to
instead examine the interaction at the visit. By incorporat-
ing three distinct perspectives and focusing on decision
making in the primary care setting, we sought to generate
hypotheses to inform interventions to increase vaccine
receipt.
Methods
This qualitative study was conducted within The Chil-
dren’s Hospital of Philadelphia (CHOP) Pediatric Research
Consortium (PeRC), a multi-state, hospital-owned, pri-
mary care practice-based research network including more
than 235,000 children and adolescents. Study practices
included 4 urban teaching practices where fewer than 35%
of patients have private insurance and 5 practices not
involved in resident teaching, where over 80% of children
are privately insured. The study was conducted in a health
system where the HPV vaccine was covered by insurance,
which allowed us to look at factors other than cost that
might impact the decision-making process.
Study design and patient population
We conducted semi-structured individual interviews with
20 mother-adolescent-clinician triads. Based on the
emphasis in the existing literature on the impact of
maternal input on HPV vaccine decision making, we
excluded male caregivers [14,15,18,26]. We purposively
sampled to achieve a balance of adolescent ages, (11-18)
and a balance of practice settings, and conducted 60
interviews between March and June 2010. No more than
three triads were chosen from each participating practice.
We sampled only attending physicians, none of whom
had specific training in adolescent medicine. Six triads
declined; 5 due to parental or clinician time constraints
and 1 due to an adolescent’s medical complexity.
Rosters of eligible patients were generated from
CHOP’s electronic health record and included all girls
ages 11-18 that had not initiated the HPV vaccine series
and also had an upcoming well-visit at one of the partici-
pating sites. We chose to focus on preventive well-visits,
as the American Academy of Pediatrics (AAP) recom-
mends that immunizations be administered by primary
care clinicians during these routine preventive visits and
the HPV vaccine is typically discussed between US
families and clinicians in this setting [27]. After a visit at
which the adolescent had an opportunity to receive the
HPV vaccine, we approached the mother, adolescent, and
clinician to introduce the study and obtain consent/
assent. Interviews were conducted immediately after the
visit, in a private room at the practice, and each member
of the triad was interviewed separately. Interviews were
conducted by either a pediatric resident (ALJ) or a non-
clinical research assistant with experience in conducting
qualitative interviews (CCH). Themes were consistent
across interviews. This study was approved by the CHOP
Institutional Review Board, an official recognized
research ethics committee.
Data collection
Through a detailed review of the relevant literature, meet-
ings of the research team, and consultation with outside
experts, we developed an interview guide to elicit parent,
adolescent and clinician perspectives on the decision to
recommend (clinician) and receive/refuse (mothers and
adolescents) adolescent vaccines (guide available upon
request). Parents and adolescents were asked about their
prior knowledge of vaccines, whether they received vac-
cines at the visit, whether vaccines were discussed with the
clinician, and how they made the final decision to either
receive or refuse available vaccine(s). We asked clinicians
to focus on the specific visit and describe the vaccine dis-
cussion, compare their presentation of HPV with other
vaccines, and describe their perception of the family’s deci-
sion. Two trained interviewers (AJS and CCH) conducted
the interviews. Themes were consistent across both inter-
viewers. Using a brief questionnaire, we collected demo-
graphic data on participants.
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Interviews were audio taped and analyzed using NVivo
qualitative data analysis software (QSR International, Mel-
bourne, Australia). Analysis was based on a modified
grounded theory approach, in which coding was inductive
and not based on an a priori coding framework [28]. To
take advantage of our study design, we analyzed data both
within and across triads. Data collection was concurrent
with data analysis, and continued until we reached satura-
tion, with no new themes emerging. Two authors (ALJ
and CCH) independently coded the interviews. Using an
iterative process, we reviewed codes, identified emerging
themes, and resolved any discrepancies through consen-
sus. Using NVivo, each transcript was linked with partici-
pants’ demographic data. After all transcripts were coded,
themes were finalized based on the consensus of the
research team. Representative verbatim comments were
selected for presentation.
Results
Nine adolescents received the HPV vaccine at the visit
and 11 adolescents did not. All 11 that did not receive
the HPV vaccine either received other routine adolescent
vaccines at their visit or were already up to date, illustrat-
ing that HPV was the only vaccine refused. Demographic
characteristics of participants are described in Table 1.
We did not observe systematic patterns of vaccine accep-
tance or refusal based on adolescent age or years of clini-
cian experience. Eight of the nine teens who accepted the
HPV vaccine were African American. We identified three
primary themes highlighted below. Verbatim comments
to support these themes are presented in the text and in
Table 2.
Parents delayed, rather than refused vaccination, and
when they expressed reluctance, clinicians were hesitant
to engage them in discussion
Only one mother in our sample was resolute in her deci-
sion never to vaccinate her daughter against HPV. Others
who declined the vaccine at the visit planned to delay or
“wait a year” and revisit the vaccine decision, as opposed
to refusing the vaccine outright. One mother said, “We’re
going to wait on [Gardasil]...she’s not even in high school
yet...we’re just going to wait and see...maybe when she’s
16 or 17.” When clinicians encountered hesitation from
parents, they tended not to “push,” instead affirming par-
ents’ preference to wait. For example, this family’s clini-
cian reported, “Is a i di t ’s up to them...they can get it now
or they can wait.” Another clinician, describing her
response to a reluctant family, said, “I’ve learned with
them to just back off, go on with the rest of the visit, and
we’ll address it again next year.”
Clinicians anticipated resistance from parents regarding
the HPV vaccine, particularly because of its perceived
association with sexual activity. One clinician whose
patient declined the HPV vaccine at the visit noted,
“HPV has so many other implications for parents...it’s
one they fight you on...because you’re suggesting that
their child is or will be sexually active soon, and they
don’tw a n tt oh e a rt h a t . ” Most parents in our sample did
associate the need for HPV vaccine with current sexual
Table 1 Characteristics of study participants
n
Mothers
Race
Black 12
White 8
Education
≤ High School Diploma 9
Some College 1
Bachelor’s Degree 5
Master’s Degree or Professional Degree 5
Occupation
Unemployed 5
Working Without Pay 2
Self-Employed 1
Working for Wages 12
Total 20
Adolescent girls
Age
11-12 10
13-15 7
16-18 3
Received HPV Vaccine*
Yes 9
No 11
Total 20
Clinicians
Race
Black 2
White 15
Other 3
Gender
Female 16
Male 4
Practice Setting
Urban Resident Teaching Practice 10
Other Practices ^ 10
Years in Practice (Post-Training)
< 10 years 3
10 - 20 years 10
> 20 years 7
Total 20
* Insurance covered HPV vaccine for all subjects.
^ Practices located in either an urban or suburban setting with primarily
privately.
insured patients and no residents.
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Theme Comment
1. Parents delayed, rather than refused vaccination, and when they expressed reluctance, clinicians were hesitant to engage them in
discussion.
Reasons for delay: children not at risk
“I don’t think she need [HPV vaccine] at this time. I guess it’s for girls that’s having...sex...and I know my daughter and she’s not into that right
now.”
Mother, age 44
“I think I would wait until she’s a little bit older, 15 or 16. I just don’t think they need it right now, at 13...it’s young.”
Mother, age 48
“Hopefully [Name] ain’t having no sex...but you never know... Hopefully they won’t be [sexually active] until they get good and grown. That’s
what we want but it might not happen.”
Mother, age 51
“I don’t think my children are at risk where they need to have it.”
Mother, age 47
“[The HPV vaccine] is appropriate for when girls start dating, and things along those lines.”
Mother, age 45
“I think there’s some parents who think ‘It’s not my kid that’s going to be having sex, so they don’t need this at all.’”
Clinician, non -teaching practice
“[Name] is a perfect example...of a girl that you’re pretty confident that at 14 is not sexually active...so you have a little bit of leeway.”
Clinician, non-teaching practice
Reasons for delay: concerns about safety and efficacy
“I probably just want to know more about it and what the risks are...It’s new to me...so I need more education on it.”
Mother, age 51
“I’d like to know the side effects of it...how long they’ve been testing it.”
Mother, age 30
“I still want to do a little more research...I’ve heard some pros and cons about it, and since we do have a longer time-line...that’s why we’re not
doing it today.”
Mother, age 43
“[Parents] had concerns about how long the vaccine’s been out and the safety, and they wanted to have more time to think about it.”
Clinician, urban teaching practice
Clinician hesitancy
“I don’t push it the same way as... [other vaccines].”
Clinician, urban teaching practice
“I will say that I only push it so far...if I had a two-month old who is refusing...IPV or something like that, I might talk to them...I might take up
much more time trying to convince them to do that, because I think that the nature of that illness is such that, you know there are devastating
consequences...Now, HPV, the truth is that a significant portion of young women will get HPV, but a very large percentage of them will also
clear HPV and not actually go on to have cervical cancer. So it’s one of those vaccines where I think it’s a good idea, but...I don’t really twist
their arm or anything.”
Clinician, urban teaching practice
“She said she’d prefer to wait and get it later...Did she give any specific concerns about why she wants to wait ...No, and I didn’t push her on that.”
Clinician, non-teaching practice
“We probably don’t press it as strong as we do with the other [teen vaccines].”
Clinician, non-teaching practice
“I’m comfortable with them waiting on the HPV vaccine; I’m not comfortable with them waiting on DTaP or meningitis.”
Clinician, non-teaching practice
2. Clinicians used one of two distinct strategies to present the HPV vaccine. Neither elicited negative responses from families.
Presenting HPV in the same was as other routine vaccines
“I mention it at 11 because that’s when the other booster vaccines are due so that helps me in my endeavor to try to vaccinate, by saying
you’re due for these vaccines.”
Clinician, urban teaching practice
“I told her about the vaccines she was due for [including HPV].”
Clinician, urban teaching practice
Presenting HPV as optional and highlighting the risks and benefits of the vaccine
“He said [HPV] was something that was optional or we could talk about it later, and the others... were not optional.”
Mother, age 39
“[The doctor] discussed the side effects....and reducing the chances of her getting the virus...that was helpful.”
Mother, age 30
“I do explain that it is optional because...it’s not like you have to get it for school or anything like that.”
Clinician, urban teaching practice
“Part of [why we don’t press the vaccine] is, at least currently, [because of the] school regulations... the parents will get messages about [the
other vaccines] but they won’t get messages about [HPV].”
Clinician, non-teaching practice
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think I’m ready for her to get [the HPV vaccine]...because
she’s a good kid and I know she ain’t out there sexually...
I’mj u s tn o tw o r r i e da b o u tt h a tr i g h tn o w . ” Clinicians
expressed difficulty in communicating to parents why the
vaccine was recommended to girls who were not yet
sexually active. One clinician, after discussing the vaccine
with a mother who declined the vaccine because she felt
h e rd a u g h t e rw a sn o ta tr i s k ,s a i d ,“I think people really
misunderstand how ineffective the vaccine is if you give
it after they start having sex... [We should think about]
how to talk to families about that.”
Some clinicians shared parents’ view that certain teens
were not at risk, and could therefore delay vaccination,
which may have influenced their decision not to pursue
further discussion. This perception was often based on
the characteristics of a child or family’sd e m o g r a p h i c
characteristics, such as socio-economic status. One clini-
cian whose patient had delayed the vaccine said, “She
hasn’t even started puberty yet...it’s a very close-knit
family, the father’s a physician, they live in the suburbs...
there’s no concern about her being sexually active any-
time soon.” The mother in this triad recalled, “[The doc-
tor] said [HPV] was something that was optional.”
Another clinician, whose patient received the vaccine,
explained, “T h ef a m i l yi sam o r eu r b a nf a m i l yt h a th a s
experienced some of the urban realities a little more than
some of my suburban families.”
Clinicians were also sensitive to parents’ worries about
the safety and efficacy of the HPV vaccine, especially in
the long-term. One clinician explained, “A lot of families
have seen advertisements about [the vaccine] and have a
lot of concerns.” Some parents cited these concerns as a
reason for delaying vaccination. One mother said, “Based
on the clinical studies I’ve seen, there’s not enough long-
term data for immunity for me... I don’t believe that the
efficacy is there.” Her 18 year old daughter explained why
she did not receive the vaccine, saying, “Ig u e s sm y
mom...wants to wait until [there is] more research on it.”
Another mother added, “Ik n o wi t ’s a fairly new vaccine,
so I kind of wanted to give it a few years out there...I’m
worried about, as these girls get older, if it will affect
their reproductive organs.”
Some clinicians did not push reluctant families to
accept the HPV vaccine because clinicians perceived it
was less important than other vaccines. For example,
one clinician in a resident teaching setting explained,
“Flu would be the example where people very frequently
don’t want to get it, and I... say I think they’re making a
very bad decision, that they’re putting their child’s life at
risk...whereas I can’t really say that about HPV.” The
mother in this triad shared this perception, accepting
other vaccines at the visit but not HPV.
Clinicians used one of two distinct strategies to present
the HPV vaccine. Neither elicited negative responses from
families
Clinicians used two distinct strategies for presenting the
HPV vaccine to families. The first was to recommend the
HPV vaccine in the same way as other adolescent vac-
cines, without providing additional details. One clinician
in a resident teaching practice whose patient received the
vaccine, explained, “Ip r e s e n t[ H P V ]l i k ei t ’sar o u t i n e
vaccine...I treat it like any other vaccine.” Clinicians who
used this approach felt that they had more success than
those that distinguished the HPV vaccine as unique. In
our sample, four of the six patients whose clinicians used
this approach received the HPV vaccine at the visit. One
clinician said, “Usually the way I present it, they get all
the vaccines. If they don’t get all the vaccines, it’s because
they don’t want any of them.” The mother in this triad
accepted the HPV vaccine, and said she was satisfied
with the vaccine discussion.
The second approach was to frame the HPV vaccine as
“optional” and highlight the risks and benefits of the vac-
cine. Five of the fourteen teens whose clinicians used this
approach received the HPV vaccine at the visit. A clinician
described, “With the required vaccines I say these are
Table 2 Themes and representative verbatim comments (Continued)
3. Teens considered themselves passive participants in decision making, even when parents and clinicians reported including them in the
process.
What did you think about not getting the vaccine?
“It doesn’t matter, I didn’t really care about it either way.”
Teen, age 13
“I think there was one [vaccine I was eligible for] but I’m not sure what it was for exactly, like what it was called.”
Teen, age 13
“I don’t like needles...why it got to be a needle? Instead of that shot up the nose like the flu.”
Teen, age 12
Was your daughter involved in the conversation?
“[My daughter] was here, but of course she didn’t want to get it...because she don’t like no needles, but I said OK.”
Mother, age 51
“[The decision] was mine. She don’t know what [the vaccine] is.”
Mother, age 44
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HPV, I say she’s also eligible to get the HPV vaccine today,
but it’sy o u rc h o i c e . ” Another clinician said, “Is a yi t ’su p
to them, that they can get it now or they can wait.” Some
clinicians who used this strategy focused on parents’ con-
cerns about the vaccine being “new.” For example, one
clinician said, “We spend more time... detailing [why we
are recommending it] because it’s newer.” Others noted
that, unlike other routine adolescent vaccines, the HPV
vaccine was not required for school attendance, so they
presented it separately. Mothers in triads where clinicians
used this strategy appreciated the additional information
clinicians provided. One mother noted, “When he
explained what...[the HPV vaccine] was used for and what
it helps prevent...I was comfortable with that.”
Clinicians had differing beliefs about how much infor-
mation they should provide families about the HPV vac-
cine. Those who used the first approach were aware of the
absence of a school mandate, but did not share this with
parents. One clinician explained, “I don’t really say what’s
required by school and what’s not, and I’ve never had any-
one ask me that.” In contrast, a clinician that employed
the second strategy said, “It’s not a required vaccine so I
do educate families that it’s a recommended vaccine...I
think families have a right to know that as part of their
decision-making...I don’t feel right in presenting some-
thing to a family as non-optional for school when that in
fact is not true.” In both groups, many clinicians described
their approach as consistent across visits. In none of the
20 triads in this sample did parents or adolescents com-
plain about the way the vaccine was presented.
Teens considered themselves passive participants in
decision making, even when parents and clinicians
reported including them in the process
Clinician, parent, and adolescent interviews consistently
revealed that teens played a minimal role in vaccine deci-
sion making. Discussion about vaccines was directed pri-
marily to the mother. Even when clinicians reported
engaging both adolescents and parents in discussion about
the vaccine, mothers were the primary decision-makers.
One 11 year old teen, when asked which vaccines she
received, said, “Yes, it’s the one that my Mom said but I
have no clue what it is. I’ve never heard of it.” Even a 16
year old who was seen alone as part of the visit did not
want to discuss the vaccine without her mother present.
All teens in our sample reported that they were satisfied
with their role in the decision making, and parents were
also satisfied with the level of teen involvement. When
asked if she would prefer to have participated more in the
discussion, one 11 year old who received the vaccine
replied, “It doesn’t matter. I could talk or not.” One
mother explained, “She didn’t really have a choice, it’sm y
decision as a parent.”
The main way that adolescents reported taking part in
t h ev a c c i n ed i s c u s s i o nw a st oe x p r e s sc o n c e r na b o u t
anticipated pain from shots. A 14 year old participant
whose mother declined the vaccine noted that she had
heard the HPV vaccine was more painful than other vac-
cines; however, even among participants who had never
heard of the HPV vaccine, pain was a primary concern.
One 11 year old who received the vaccine, when asked if
she would have liked information about vaccines prior to
the visit, said, “No, I just don’t want to get it. I don’tl i k e
shots. They hurt.” Five teens who expressed concern
about pain received the vaccine, and four did not, sug-
gesting that pain may not have impacted vaccine receipt
in our sample. While some teens hinted at the connec-
tion between maturity and the vaccine, in contrast to
their parents, none of the adolescents interviewed men-
tioned sex in discussing the vaccine (Table 2).
Discussion
We conducted this qualitative study with mothers, adoles-
cents, and clinicians to better understand discrepancies
between research findings that show high HPV vaccine
acceptability among parents and adolescents, and high
clinician intention to recommend the vaccine, but low
rates of receipt. By considering the perspectives within and
across each triad interviewed, we identified several themes
that may help explain low vaccination rates and inform
future interventions.
Our study identified that parents tended to delay,
rather than refuse vaccination, and that when parents
resist vaccination, clinicians often do not directly address
their concerns, contributing to the postponement of vac-
cination. We found several explanations for this pattern.
Confirming results from prior studies, parent concerns
about vaccine safety and efficacy were reasons parents
chose to delay [18,26,29]. However, we found that con-
cerns related to sex were also salient. Parents’ perception
that teens were not at risk because they were not thought
to be currently sexually active often prompted the deci-
sion to decline the vaccine and “wait a year” before revi-
siting the decision. This pattern is concerning since rates
of attendance at preventive visits decline after age 11
years and 3 doses are needed for full protection [9,30].
These delays may also be prolonged since parents are
known to underestimate their children’s sexual activity
[31,32]. Further research using a longitudinal design
would be useful to determine the length of delays and to
identify factors that influence when and how vaccine
delay turns into vaccine refusal.
Some clinicians, like parents, believed that certain chil-
dren, especially those in the target age group for vaccina-
tion, were not at risk, which may have contributed to
their reluctance to encourage vaccination. This percep-
tion is concerning since clinicians sometimes reported
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and socio-economic status to determine a child’sr i s k .
While these characteristics are correlated with sexual
initiation on a population level, assessing risk on an indi-
vidual level using this approach is likely to miss at-risk
children and may lead to inequalities if certain groups
receive stronger vaccine recommendations [6]. Clinicians
also differed in their interpretation of the importance of
HPV compared with other vaccines, with some asserting
that vaccines such as influenza or the meningitis vaccine
justified a stronger recommendation than the HPV vac-
cine. Finally, some clinicians were uncomfortable enga-
ging families about HPV because it is a sexually
transmitted infection (STI) and therefore a sensitive topic
for families, a finding that confirms prior qualitative
research on HPV vaccine communication [33]. In this
context, clinicians were hesitant to “push” for vaccination
because of concerns about the impact of this approach
on their long-term relationship with families.
As these examples reveal, and as others have found,
[33,34] clinicians in our sample identified challenges in
communicating with ambivalent families and in presenting
the scientific evidence for the HPV vaccine. Effective inter-
personal and communication skills as well as knowledge of
how to educate families, two areas identified as challenges
by clinicians in our study, have been recognized as core
competencies by the U.S. Academic Council on Graduate
Medical Education (ACGME) and prioritized by policy-
makers focused on improving healthcare quality [35,36].
H o w e v e r ,t h e s es k i l l sh a v en ot historically been empha-
sized in medical education. Our results highlight the
potential benefit of interventions to improve communica-
tion between clinicians and parents. Specifically, in the set-
ting of HPV, brief motivational interviews have been
suggested as a strategy to engage families who are ambiva-
lent [21]. This technique has been shown to help families
identify and clinicians address underlying concerns in a
way that allows the clinician to convey respect and empa-
thy while also sharing medical information [37]. Our
results suggest that evaluation of this technique in the set-
ting of HPV vaccine decision making is warranted. Addi-
tional work is also needed to help clinicians better
recognize their own underlying concerns and biases and
the ways in which these may impact the presentation and
delivery of evidence-based care.
Overall, three prototypes for medical decision making
have been defined in the literature: (1) a paternalistic
model in which the clinician makes the decision and com-
municates it to the family, (2) an informed model in which
the patient/family gathers information from the clinician
and other sources and reaches a decision, and (3) a shared
model in which medical and personal information is
exchanged and the clinician and family jointly reach a
decision [38]. We found that clinicians in our study
adopted either the paternalistic or shared model in dis-
cussing HPV. Those who used the paternalistic approach
believed that they had more success in vaccinating adoles-
cents by presenting HPV as a standard part of the care of
early adolescents, without providing additional informa-
tion about the vaccines. In our sample this appeared to be
true, especially among African American patients. How-
ever, this qualitative study was not designed to formally
test this association. In contrast, those who shared in deci-
sion making were less focused on the outcome of vaccine
receipt and instead emphasized the importance of invol-
ving families in the decision and discussing risks and bene-
fits in detail. Further study is needed to evaluate the
impact of both these approaches on decision making,
patient satisfaction, and vaccine receipt in diverse primary
care populations. Results of this work will help to inform
how clinicians should be trained to most effectively
address sensitive topics such as HPV vaccination.
Teens in our sample characterized themselves as playing
a passive role in vaccine decision making, suggesting that
additional strategies for educating and engaging teens
about the HPV vaccine as well as other adolescent vac-
cines may be warranted. Previous studies have found that
adolescents are interested in HPV and other STI vaccines;
[21] however, this interest may not result in active partici-
pation in the primary care setting. Though the American
Academy of Pediatrics (AAP) Committee on Bioethics has
emphasized the importance of adolescent involvement in
decision making,[39] our results suggest that, at least in
the short-term, efforts to improve HPV vaccination rates
among younger adolescents in the primary care setting
may be most effective if targeted primarily at parents.
Mothers’ approval of vaccination has also been shown to
predict vaccine acceptance among older teens,[15] which
underscores their central role in decision making.
Teenagers in our study primarily contributed to the vac-
cine discussion by expressing concerns about pain, a find-
ing supported by other recent qualitative studies [40,41].
Although mothers acknowledged their teens’ concerns,
the conversation with the clinician typically focused on the
mother’s distinct concerns. Unlike mothers, teenagers in
our study did not appear to associate the HPV vaccine
with sex. Other studies have shown that some parents
worry that vaccination might encourage sexual activity
among teenagers;[42] however, our results should help
allay these fears. Consistent with findings that teens had
limited knowledge about cervical cancer, Papanicolaou
smears,[43] and the HPV virus, [40,41] teens in our study,
most of whom were 15 or younger, knew very little about
what the HPV vaccine prevented. Among those who had
heard of the vaccine, none mentioned sexual transmission.
Educating teens about sexuality and sexually transmitted
infection prevention has not been shown to promote ado-
lescent sexual behavior,[44] a fact that primary care
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Page 7 of 9pediatricians may find helpful to share with parents speci-
fically concerned about the vaccine’s association with sex.
This study had several limitations. We did not observe
the visits; therefore, our results are based on participant
report. Our sample included mostly younger teens, all of
whom were accompanied by a parent; they may be more
inclined than older or unaccompanied teens to focus on
immediate concerns, such as pain, rather than future
benefits. We purposively sampled from pediatric primary
care practices within one health system and results may
not be generalizable to all settings. As a qualitative study,
our aim was to generate themes to enhance our under-
standing of HPV decision making. Nonetheless, we did
assemble a sample of families with diverse racial and edu-
cational backgrounds and clinicians working in varied
practice settings with a wide range of experience, which
mitigates the impact of selection bias. Our finding that
teens did not appear to associate the HPV vaccine with
sex may have been biased by teens’ unwillingness to dis-
cuss the issue of sex with the interviewers. Additionally,
participants were aware that we were studying adolescent
vaccination and this could have potentially biased com-
ments. Still, we elicited a broad and diverse set of
responses suggesting that participants openly discussed
HPV vaccine decision making.
Conclusions
By exploring adolescent, maternal, and clinician perspec-
tives on HPV vaccine decision making at the point of care,
we identified several factors that may help explain low
rates of receipt. These include parents’ tendency to delay
vaccination based on beliefs that their teens were not cur-
rently at risk for acquiring HPV and clinician reluctance
to engage ambivalent parents about their concerns. We
also found that teens were passive participants in vaccine
decision making, and that clinicians used two distinct
approaches in presenting the vaccine to families. In formu-
lating interventions to improve vaccine delivery in primary
care, it will be important to develop strategies to promote
effective communication between clinicians and parents at
the first opportunity, to evaluate approaches such as moti-
vational interviewing to help clinicians engage reluctant
parents in discussion, and to measure the impact of dis-
tinct clinician decision making styles on HPV vaccine
delivery.
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